Fast drug-gene test results for cardiologists before the prescription is final
TL;DR Genorder is a narrow pharmacogenomic test that reports in about two days, and it starts with CYP2C19, the gene that decides whether clopidogrel works. Hospitals and cardiologists order it, patients pay a few thousand rupees and the result stays useful for life. It can work because today's Indian tests are broad but slow.
Clopidogrel only works once a liver enzyme called CYP2C19 switches it on. Plenty of Indians carry gene variants that weaken that enzyme. In a Delhi army hospital cohort of 60 angioplasty patients, 37% were intermediate metabolisers and 15% were poor metabolisers, and the authors noted that this kind of testing is not routine in Indian practice[1]. At one Hyderabad hospital group, about 30% of the first 1,500-plus patients tested were on standard prescriptions their genes made unsuitable, by the hospital's own account[2].
And the tests that do exist are slow. A widely sold Indian panel reports in 27 days[4], which is useless to a cardiologist picking an antiplatelet drug after a stent because nobody can wait a month for that answer.
First, the regulatory bit - Genorder is a laboratory genotype test plus prescriber decision support. It does not diagnose disease or prescribe. The doctor decides. The lab side falls under clinical-establishment rules and the test kits under the Medical Devices Rules 2017. Does the reporting software count as a medical device? India has no clear ruling yet, so get a regulatory opinion early.
Genorder starts with one decision that has a strong guideline behind it. The 2022 CPIC guidance says intermediate and poor CYP2C19 metabolisers having angioplasty should get prasugrel or ticagrelor instead of standard clopidogrel where safe[3]. A cheek swab or blood sample taken at admission goes to a partner NABL lab running a small, validated genotyping panel, and the cardiologist gets a one-page result on a chat app and in the hospital record within 48 hours, with the phenotype and what the guideline says.
Later panels add warfarin dosing genes and a few psychiatry and epilepsy drug pairs, one at a time and only where the evidence is graded. Each patient keeps a lifetime card that any future prescriber can read. The bet is on speed at the point of prescribing, because the 165-drug report already exists.
The patient pays, usually as a line on the angioplasty bill, but the cardiologist is the one who has to want it. Indian prices today run from ₹5,000 at that hospital group[2] to ₹6,569–7,299 for one genomics startup's broad panel[4]. A narrow panel should sell below that, at my estimate ₹2,000–3,500. Hospitals are the real buyer - they choose the lab, set the price and decide whether testing becomes a default order. In the US, one psychiatric drug-gene test charges self-pay patients up to US$330 (about ₹32,000)[6], which shows how far below Indian prices sit.
The CPIC guideline was strengthened in February 2022 to a strong recommendation for intermediate metabolisers in angioplasty[3]. In October 2025 the Hyderabad group began testing patients before prescriptions were written and talked publicly about pushing the price to ₹2,000–3,000[2]. A big lab chain launched a 194-drug panel in October 2024[7]. So hospitals now know the test exists. What they lack is one fast enough to use.
Towards Healthcare puts India's pharmacogenomics market at US$267 million in 2025 (about ₹2,580 Cr), growing 12.6% a year to 2035[5]. Its method sits behind a paywall, so treat it as a rough ceiling and not a target.
The narrower and more useful number isn't public - how many angioplasty patients get a CYP2C19 test. My guess is very few, given the Delhi authors' comment[1]. The signal that matters is that one large hospital tested 2,000 patients in its first programme[2].
One genomics startup's panel covers 165-plus drugs from a blood sample and reports in about a month[4]. The Hyderabad hospital group runs an in-house programme with a genomics partner at ₹5,000, with reports in roughly 12 days[2]. The lab chain offers an exome-based panel covering 59 genes[7]. Abroad, one US test maker built a business on psychiatric drug-gene reports paid for largely by insurers[6].
All of them sell breadth. None is built around a two-day answer for one acute decision.
| Difficulty | Moderate (46/100) |
| Starting capital | ₹1.1–2.1 Cr |
| Time to launch | 6–9 months |
Genotyping a handful of variants is cheap and well understood. The hard parts are logistics and belief. Samples have to reach the lab and results have to come back inside 48 hours from hospitals in several cities, and on top of that cardiologists must trust the result enough to switch drugs when the outcome evidence from Indian cohorts is mixed, which hands sceptics a reason to wait.
Yes. A genetic test is a lab service, so the lab and its kits need approvals before the first sample.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI add its own dosing advice or decide the drug. Report the guideline as written and leave the choice with the doctor.
Want to work out the AI layer for Genorder? Talk to Yash →
Here's what can go south -
I like this one for a founder with clinical-lab or diagnostics sales experience who is happy to sell one test well before selling twenty. If you're picturing a consumer genomics app then it's a poor fit, honestly.
Before you build anything, get three cath-lab heads to agree in writing that a 48-hour result would change what they prescribe, and find out at what price.
My estimate is ₹1.1–2.1 Cr to launch, covering panel validation with a partner lab, logistics across cities and hospital sales. The kit breaks it down line by line.
Yes. The lab needs clinical establishment registration where the state requires it, and the test kits need licences under the Medical Devices Rules 2017.
Yes, and US drug-gene testing shows the market abroad. Lab, kit and insurance rules change by country, so check with your own regulator first.
The free Genorder validation kit has the line-by-line capital breakdown, the effort scoring, the lab and medical-device rules checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for cardiologists and hospital buyers, and 5 assumptions to test. Download the kit →
Thinking about building Genorder or something close to it? The make-or-break work is proving that a 48-hour result changes real prescriptions in one hospital, and that's the kind of thing I help founders figure out. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.